AR
Alexander Rudensky, Ph.D.
Chairman of the immunology program and Director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center
Coherus OncologyTherapeutic Areas
Coherus Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LOQTORZI® (toripalimab-tpzi) | 1L Nasopharyngeal Carcinoma (combo with chemotherapy) | Approved |
| Tagmokitug (CHS-114) | 4L+ Colorectal Cancer (combo with toripalimab) | Phase 2 |
| Casdozokitug | 1L Hepatocellular Carcinoma (combo with toripalimab + bevacizumab) | Phase 2 |
Leadership Team at Coherus Oncology
DM
Dennis M. Lanfear
President & Chief Executive Officer, Chairman of the Board
RD
Rosh Dias, M.D., M.R.C.P.
Chief Medical Officer
TL
Theresa LaVallee, Ph.D.
Chief Scientific & Development Officer
AS
Arvind Sood
Chief Strategy and Corporate Affairs Officer
SG
Sameer Goregaoker
Chief Commercial Officer
BM
Bryan McMichael
Chief Financial Officer
RS
Rebecca Sunshine
Chief Human Resources Officer
AR
Andy Rittenberg
Chief Legal Officer
CG
Carrie Graham
Vice President, Investor Relations and Advocacy
MW
Mats Wahlström
Lead Director, Executive Chairman of KMG Capital Partners, LLC